{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:24:31Z","timestamp":1794255871614,"version":"4.9.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12325-026-03681-6","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:42:19Z","timestamp":1783928539000},"page":"5327-5347","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Uncontrolled Hypertension Prevalence, Characteristic Profiles, and Risk of Cardiorenal and Metabolic Outcomes: Insights from the EnligHTN Study"],"prefix":"10.1007","volume":"43","author":[{"given":"Terry","family":"McCormack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi R.","family":"Ben Dor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Giannoula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Coto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty M.","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Franz\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Su\u00e1rez Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper N.","family":"Bech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"issue":"12","key":"3681_CR1","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874\u20132071.","journal-title":"J Hypertens"},{"issue":"38","key":"3681_CR2","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912\u20134018.","journal-title":"Eur Heart J"},{"issue":"6","key":"3681_CR3","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334\u201357.","journal-title":"Hypertension"},{"issue":"33","key":"3681_CR4","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u2013104.","journal-title":"Eur Heart J"},{"issue":"10","key":"3681_CR5","first-page":"e212","volume":"82","author":"DW Jones","year":"2025","unstructured":"Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension. 2025;82(10):e212\u2013316.","journal-title":"Hypertension"},{"issue":"6","key":"3681_CR6","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive summary: A report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018;71(6):1269\u2013324.","journal-title":"Hypertension"},{"issue":"10258","key":"3681_CR7","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","volume":"396","author":"GBD 2019 Risk Factors Collaborators","year":"2020","unstructured":"GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223\u201349.","journal-title":"Lancet"},{"issue":"4","key":"3681_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","volume":"16","author":"KT Mills","year":"2020","unstructured":"Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223\u201337.","journal-title":"Nat Rev Nephrol"},{"key":"3681_CR9","unstructured":"Our World in Data. IHME, global burden of disease, \u201cGlobal burden of disease - Risk factors\". 2024. https:\/\/ourworldindata.org\/grapher\/number-of-deaths-by-risk-factor. Accessed 27 June 2025."},{"issue":"7","key":"3681_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/j.1751-7176.2008.08189.x","volume":"10","author":"DA Sica","year":"2008","unstructured":"Sica DA. The kidney and hypertension: causes and treatment. J Clin Hypertens (Greenwich). 2008;10(7):541\u20138.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"3681_CR11","unstructured":"World Health Organization. Hypertension. 2023. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hypertension. Accessed 24 February 2025"},{"issue":"7","key":"3681_CR12","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1097\/HJH.0b013e32832a9ba3","volume":"27","author":"TA Gaziano","year":"2009","unstructured":"Gaziano TA, Bitton A, Anand S, Weinstein MC. The global cost of nonoptimal blood pressure. J Hypertens. 2009;27(7):1472\u20137.","journal-title":"J Hypertens"},{"issue":"10305","key":"3681_CR13","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0140-6736(21)01921-8","volume":"398","author":". Blood Pressure Lowering Treatment T","year":"2021","unstructured":"Blood Pressure Lowering Treatment Trialists' Collaboration. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet. 2021;398(10305):1053\u201364.","journal-title":"Lancet"},{"issue":"7","key":"3681_CR14","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1001\/jamacardio.2017.1421","volume":"2","author":"JD Bundy","year":"2017","unstructured":"Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: A systematic review and network meta-analysis. JAMA Cardiol. 2017;2(7):775\u201381.","journal-title":"JAMA Cardiol"},{"issue":"10022","key":"3681_CR15","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957\u201367.","journal-title":"Lancet"},{"issue":"10304","key":"3681_CR16","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","volume":"398","author":"NCD Risk Factor Collaboration","year":"2021","unstructured":"NCD Risk Factor Collaboration. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957\u201380.","journal-title":"Lancet"},{"issue":"12","key":"3681_CR17","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1097\/HJH.0000000000001502","volume":"35","author":"H Durand","year":"2017","unstructured":"Durand H, Hayes P, Morrissey EC, et al. Medication adherence among patients with apparent treatment-resistant hypertension: systematic review and meta-analysis. J Hypertens. 2017;35(12):2346\u201357.","journal-title":"J Hypertens"},{"issue":"2","key":"3681_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.34067\/KID.0005362021","volume":"3","author":"MT Eadon","year":"2022","unstructured":"Eadon MT, Maddatu J, Moe SM, et al. Pharmacogenomics of hypertension in CKD: The CKD-PGX study. Kidney360. 2022;3(2):307\u201316.","journal-title":"Kidney360"},{"issue":"1","key":"3681_CR19","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13098-022-00899-6","volume":"14","author":"P C\u0103lin","year":"2022","unstructured":"C\u0103lin P, Viorel M, Luchiana P, Mihaela C, Lavinia P. Masked nocturnal hypertension as a result of high prevalence of non-dippers among apparently well-controlled hypertensive patients with type 2 diabetes mellitus: data from a prospective study. Diabetol Metab Syndr. 2022;14(1):130.","journal-title":"Diabetol Metab Syndr"},{"issue":"9","key":"3681_CR20","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1161\/CIRCULATIONAHA.111.030189","volume":"124","author":"BM Egan","year":"2011","unstructured":"Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124(9):1046\u201358.","journal-title":"Circulation"},{"issue":"7","key":"3681_CR21","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s11739-023-03376-8","volume":"18","author":"S Romano","year":"2023","unstructured":"Romano S, Rigon G, Albrigi M, et al. Hypertension, uncontrolled hypertension and resistant hypertension: prevalence, comorbidities and prescribed medications in 228,406 adults resident in urban areas. A population-based observational study. Intern Emerg Med. 2023;18(7):1951\u20139.","journal-title":"Intern Emerg Med"},{"issue":"1","key":"3681_CR22","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1038\/s41598-020-58685-1","volume":"10","author":"M Cherfan","year":"2020","unstructured":"Cherfan M, Vall\u00e9e A, Kab S, et al. Unhealthy behaviors and risk of uncontrolled hypertension among treated individuals-The CONSTANCES population-based study. Sci Rep. 2020;10(1):1925.","journal-title":"Sci Rep"},{"issue":"10","key":"3681_CR23","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.mayocp.2013.06.017","volume":"88","author":"JJ Sim","year":"2013","unstructured":"Sim JJ, Bhandari SK, Shi J, et al. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc. 2013;88(10):1099\u2013107.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"3681_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrneph.2012.260","volume":"9","author":"PA Sarafidis","year":"2013","unstructured":"Sarafidis PA, Georgianos P, Bakris GL. Resistant hypertension\u2013its identification and epidemiology. Nat Rev Nephrol. 2013;9(1):51\u20138.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"3681_CR25","doi-asserted-by":"publisher","first-page":"9418","DOI":"10.1038\/s41598-018-27377-2","volume":"8","author":"D Zhou","year":"2018","unstructured":"Zhou D, Xi B, Zhao M, Wang L, Veeranki SP. Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study. Sci Rep. 2018;8(1):9418.","journal-title":"Sci Rep"},{"issue":"1","key":"3681_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jash.2010.02.002","volume":"4","author":"AS Iyer","year":"2010","unstructured":"Iyer AS, Ahmed MI, Filippatos GS, et al. Uncontrolled hypertension and increased risk for incident heart failure in older adults with hypertension: findings from a propensity-matched prospective population study. J Am Soc Hypertens. 2010;4(1):22\u201331.","journal-title":"J Am Soc Hypertens"},{"key":"3681_CR27","doi-asserted-by":"publisher","DOI":"10.2196\/42190","volume":"9","author":"SH Oh","year":"2023","unstructured":"Oh SH, Kim D, Hwang J, Kang JH, Kwon Y, Kwon JW. Association of uncontrolled hypertension or diabetes mellitus with major adverse cardiovascular events and mortality in South Korea: population-based cohort study. JMIR Public Health Surveill. 2023;9:e42190.","journal-title":"JMIR Public Health Surveill"},{"issue":"2","key":"3681_CR28","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1161\/HYPERTENSIONAHA.115.06487","volume":"67","author":"G Thomas","year":"2016","unstructured":"Thomas G, Xie D, Chen HY, et al. Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: Report from the chronic renal insufficiency cohort study. Hypertension. 2016;67(2):387\u201396.","journal-title":"Hypertension"},{"issue":"14","key":"3681_CR29","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","volume":"393","author":"JM Flack","year":"2025","unstructured":"Flack JM, Azizi M, Brown JM, et al. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med. 2025;393(14):1363\u201374.","journal-title":"N Engl J Med"},{"issue":"5","key":"3681_CR30","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jama.2025.9413","volume":"334","author":"M Saxena","year":"2025","unstructured":"Saxena M, Laffin L, Borghi C, et al. Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the launch-HTN randomized clinical trial. JAMA. 2025;334(5):409\u201318.","journal-title":"JAMA"},{"key":"3681_CR31","unstructured":"Alnylam Pharmaceuticals. Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3). https:\/\/clinicaltrials.gov\/study\/NCT06272487. Accessed 6 February 2026."},{"issue":"5","key":"3681_CR32","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1007\/s40615-022-01431-2","volume":"10","author":"DM Cummings","year":"2023","unstructured":"Cummings DM, Adams A, Patil S, et al. Treatment intensity, prescribing patterns, and blood pressure control in rural Black patients with uncontrolled hypertension. J Racial Ethn Health Disparities. 2023;10(5):2505\u201312.","journal-title":"J Racial Ethn Health Disparities"},{"issue":"1","key":"3681_CR33","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1186\/s12872-024-04161-x","volume":"24","author":"Y Lu","year":"2024","unstructured":"Lu Y, Keeley EC, Barrette E, et al. Use of electronic health records to characterize patients with uncontrolled hypertension in two large health system networks. BMC Cardiovasc Disord. 2024;24(1):497.","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"3681_CR34","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12872-023-03357-x","volume":"23","author":"F Farhadi","year":"2023","unstructured":"Farhadi F, Aliyari R, Ebrahimi H, Hashemi H, Emamian MH, Fotouhi A. Prevalence of uncontrolled hypertension and its associated factors in 50\u201374 years old Iranian adults: a population-based study. BMC Cardiovasc Disord. 2023;23(1):318.","journal-title":"BMC Cardiovasc Disord"},{"key":"3681_CR35","doi-asserted-by":"publisher","first-page":"6912839","DOI":"10.1155\/2022\/6912839","volume":"2022","author":"C Chotruangnapa","year":"2022","unstructured":"Chotruangnapa C, Thammarux T, Thongdang P. Prevalence and clinical characteristics including patterns of antihypertensive drug administration of the different home blood pressure phenotypes in treated hypertensive patients. Int J Hypertens. 2022;2022:6912839.","journal-title":"Int J Hypertens"},{"issue":"10","key":"3681_CR36","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/jch.14699","volume":"25","author":"C Darricarrere","year":"2023","unstructured":"Darricarrere C, Jacquot E, Bricout S, Louis C, B\u00e9nard M, Poulter NR. Uncontrolled blood pressure and therapeutic inertia in treated hypertensive patients: A retrospective cohort study using a UK general practice database. J Clin Hypertens (Greenwich). 2023;25(10):895\u2013904.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"11","key":"3681_CR37","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1111\/jch.14041","volume":"22","author":"C LaVallee","year":"2020","unstructured":"LaVallee C, Rascati KL, Gums TH. Antihypertensive agent utilization patterns among patients with uncontrolled hypertension in the United States. J Clin Hypertens (Greenwich). 2020;22(11):2084\u201392.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"2","key":"3681_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e13258","volume":"9","author":"EM Ammann","year":"2023","unstructured":"Ammann EM, O\u2019Brien ES, Milentijevic D, et al. Characteristics, management, and blood pressure control in patients with apparent resistant hypertension in the US. Heliyon. 2023;9(2):e13258.","journal-title":"Heliyon"},{"issue":"1","key":"3681_CR39","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/0962280208092347","volume":"18","author":"PG Arbogast","year":"2009","unstructured":"Arbogast PG, Ray WA. Use of disease risk scores in pharmacoepidemiologic studies. Stat Methods Med Res. 2009;18(1):67\u201380.","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"3681_CR40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.2202\/1544-6115.1691","volume":"10","author":"BA Goldstein","year":"2011","unstructured":"Goldstein BA, Polley EC, Briggs FB. Random forests for genetic association studies. Stat Appl Genet Mol Biol. 2011;10(1):32.","journal-title":"Stat Appl Genet Mol Biol"},{"issue":"2","key":"3681_CR41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/biomet\/asn004","volume":"95","author":"BB Hansen","year":"2008","unstructured":"Hansen BB. The prognostic analogue of the propensity score. Biometrika. 2008;95(2):8.","journal-title":"Biometrika"},{"issue":"1","key":"3681_CR42","doi-asserted-by":"publisher","first-page":"2165901","DOI":"10.1080\/08037051.2023.2165901","volume":"32","author":"C Beger","year":"2023","unstructured":"Beger C, Mayerb\u00f6ck A, Klein K, et al. Current practice of blood pressure measurement in Germany: a nationwide questionnaire-based survey in medical practices. Blood Press. 2023;32(1):2165901.","journal-title":"Blood Press"},{"key":"3681_CR43","doi-asserted-by":"crossref","unstructured":"Tapela N, Collister J, Clifton L, Turnbull I, Rahimi K, Hunter DJ. Prevalence and determinants of hypertension control among almost 100 000 treated adults in the UK. Open Heart. 2021;8(1):e001461.","DOI":"10.1136\/openhrt-2020-001461"},{"issue":"12","key":"3681_CR44","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jama.2020.14545","volume":"324","author":"P Muntner","year":"2020","unstructured":"Muntner P, Hardy ST, Fine LJ, et al. Trends in blood pressure control among US adults with hypertension, 1999\u20132000 to 2017\u20132018. JAMA. 2020;324(12):1190\u2013200.","journal-title":"JAMA"},{"issue":"1","key":"3681_CR45","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12916-021-01963-0","volume":"19","author":"R Philip","year":"2021","unstructured":"Philip R, Beaney T, Appelbaum N, et al. Variation in hypertension clinical practice guidelines: a global comparison. BMC Med. 2021;19(1):117.","journal-title":"BMC Med"},{"issue":"8","key":"3681_CR46","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/jch.14701","volume":"25","author":"G Bakris","year":"2023","unstructured":"Bakris G, Chen C, Campbell AK, Ashton V, Haskell L, Singhal M. Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus. J Clin Hypertens (Greenwich). 2023;25(8):737\u201347.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"6","key":"3681_CR47","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1093\/ajh\/hpae020","volume":"37","author":"G Bakris","year":"2024","unstructured":"Bakris G, Chen C, Campbell AK, Ashton V, Haskell L, Singhal M. Real-world impact of blood pressure control in patients with apparent treatment-resistant or difficult-to-control hypertension and Stages 3 and 4 chronic kidney disease. Am J Hypertens. 2024;37(6):438\u201346.","journal-title":"Am J Hypertens"},{"issue":"6","key":"3681_CR48","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1097\/HJH.0000000000002398","volume":"38","author":"AJ Lawson","year":"2020","unstructured":"Lawson AJ, Hameed MA, Brown R, et al. Nonadherence to antihypertensive medications is related to pill burden in apparent treatment-resistant hypertensive individuals. J Hypertens. 2020;38(6):1165\u201373.","journal-title":"J Hypertens"},{"issue":"1","key":"3681_CR49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.23876\/j.krcp.21.099","volume":"41","author":"H Lee","year":"2022","unstructured":"Lee H, Kwon SH, Jeon JS, Noh H, Han DC, Kim H. Association between blood pressure and the risk of chronic kidney disease in treatment-na\u00efve hypertensive patients. Kidney Res Clin Pract. 2022;41(1):31\u201342.","journal-title":"Kidney Res Clin Pract"},{"issue":"11","key":"3681_CR50","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/hr.2015.72","volume":"38","author":"MJ Kim","year":"2015","unstructured":"Kim MJ, Lim NK, Choi SJ, Park HY. Hypertension is an independent risk factor for type 2 diabetes: the Korean genome and epidemiology study. Hypertens Res. 2015;38(11):783\u20139.","journal-title":"Hypertens Res"},{"issue":"3","key":"3681_CR51","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/joim.13678","volume":"294","author":"G Mancia","year":"2023","unstructured":"Mancia G, Cappuccio FP, Burnier M, et al. Perspectives on improving blood pressure control to reduce the clinical and economic burden of hypertension. J Intern Med. 2023;294(3):251\u201368.","journal-title":"J Intern Med"},{"issue":"4","key":"3681_CR52","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005641","volume":"96","author":"TM Abegaz","year":"2017","unstructured":"Abegaz TM, Shehab A, Gebreyohannes EA, Bhagavathula AS, Elnour AA. Nonadherence to antihypertensive drugs: A systematic review and meta-analysis. Medicine (Baltimore). 2017;96(4):e5641.","journal-title":"Medicine (Baltimore)"}],"updated-by":[{"DOI":"10.1007\/s12325-026-03795-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03681-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03681-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03681-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:02:11Z","timestamp":1794254531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03681-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3681"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03681-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to update in figure 3.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-026-03795-x","URL":"https:\/\/doi.org\/10.1007\/s12325-026-03795-x","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Terry McCormack declares consulting\/speaker fees: AstraZeneca, Daiichi Sankyo, Medtronic, Novartis. Tom Norris, Alexia Giannoula, Esteban Coto, Kirsty M. Rhodes, and Stefan Franz\u00e9n declare employment at the time of the study: AstraZeneca; stock\/shares: AstraZeneca. Kirsty M. Rhodes is a current employee of GlaxoSmithKline and declares stock\/shares. Carmen Su\u00e1rez Fern\u00e1ndez declares consulting fees: Bayer, Boehringer Ingelheim, Novartis and Daiichi Sankyo. Joachim Weil declares consulting fees: AstraZeneca, Daiichi Sankyo, Novartis; advisory council or committees: Medtronic, ReCor. Naomi R. Ben Dor declares consulting fees: AstraZeneca. Jesper N. Bech declares consulting fees: AstraZeneca; advisory council or committees: AG, AstraZeneca, Bayer. Vivek Bhalla declares grants\/consulting fees: AHA, Idorsia, Medtronic, NIH; advisory council or committees: AHA, AMA, AstraZeneca, Bayer, Idorsia, Medtronic, Relypsa; stock\/shares: Nephrogen, Pyrames.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with ethical principles consistent with the Declaration of Helsinki and International Conference on Harmonization of Good Clinical Practice, and applicable legislation on non-interventional and\/or observational studies. The protocol for this study was approved by CPRD (protocol number 24_004211). Ethical approval was also provided by the ethics committee of San Carlos Clinic Hospital (Madrid, Spain; approval ID: 24\/545-O-M_NoSP) and the Meuhedet Health Organization (Israel; approval ID: 0025\u201324-MEU). In the other participating countries, ethical approval was not required. Disease Analyzer (Germany) includes only anonymized data in compliance with the regulations of the applicable data protection laws. German law allows the use of anonymous electronic medical records for research purposes. According to this legislation, it is not necessary to obtain informed consent from patients or approval from a medical ethics committee for this type of observational study that contains no directly identifiable data. Because patients were only queried as aggregates and no protected health information was available for queries, no Institutional Review Board approval was required for the use of this database or the completion of this study. Use of IQVIA Ambulatory EMR-US linked with IQVIA PharMetrics\u00ae Plus Closed Health Plan claims (US) is permitted under US law when data are de-identified and used under contractual and privacy safeguards. PharMetrics Plus contains Health Insurance Portability and Accountability Act (HIPAA)\u2011compliant, de\u2011identified claims. Once data are de-identified per HIPAA\u2019s Safe Harbor or Expert Determination standards, HIPAA no longer requires individual authorization (consent) for secondary use and disclosure. IQVIA licenses these data to users under data use agreements that restrict re-identification and regulate use. Informed consent to use these de-identified data was not required. Permission to analyse and publish these data was received by each database owner.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}